Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.
Anna WawruszakEstera OkonIlona TelejkoArkadiusz CzerwonkaJarogniew LuszczkiPublished in: Pharmacological reports : PR (2022)
CAM might be considered a potential therapeutic agent individually or in combined therapy with PAX against luminal or TNBC.